You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Best Practices in Diagnosing and Managing EGFR Exon 20 Insertion-Mutated NSCLC: Current and Future Outlook

  • Authors: D. Ross Camidge, MD, PhD; Rosario García Campelo, MD; Ignacio I. Wistuba, MD
  • CME / ABIM MOC Released: 10/1/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 10/1/2022
Start Activity


Target Audience and Goal Statement

This activity is intended for hematologists and oncologists, pathologists, and pulmonology specialists.

The goal of this activity is to increase clinicians' awareness of exon 20 insertions within EGFR-mutated non-small cell lung cancer (NSCLC), their detection and diagnosis, and the potential role of emerging targeted therapies in the treatment paradigm for EGFR exon 20 insertion mutations in NSCLC.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Biology of EGFR exon 20 insertion mutations in NSCLC
    • Clinical trial data investigating new and emerging therapies targeting EGFR exon 20 insertion mutations in NSCLC
  • Have greater competence related to
    • Applying best practices for diagnosing EFGR exon 20 insertion mutations
  • Demonstrate greater confidence in their ability to
    • Recognize the impact of EGFR exon 20 insertion mutations on the development of new therapies for patients with advanced NSCLC


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

All of the relevant financial relationships listed for these individuals have been mitigated.


Faculty

  • D. Ross Camidge, MD, PhD

    Professor of Medicine/Oncology
    Joyce Zeff Chair in Lung Cancer Research
    Director of Thoracic Oncology
    University of Colorado Cancer Center
    Aurora, Colorado, United States

    Disclosures

    Disclosure: D. Ross Camidge, MD, PhD, has the following relevant financial relationships: 
    Advisor or consultant for: Amgen; Anchiarno; Apollomics; AstraZeneca; Bio-Thera; Bristol Myers Squibb; Daiichi-Sankyo; Eisai; EMD Serono; GlaxoSmithKline; Helsinn; Janssen; Mersana; OnKure; Pfizer; Qilu; Roche; Sanofi; Seattle Genetics; Takeda
    Grants for clinical research from: Abbvie; AstraZeneca; Bristol Myers Squibb; GlaxoSmithKline; Hansoh; Inhibrix; Karyopharm; Lycera; Medimmune; Merck Sharp & Dohme; Pfizer; Phosplatin; Psioxus; Rain; Roche/Genentech; Seattle Genetics; Symphogen; Takeda; Tolero

  • Rosario García Campelo, MD

    Head of the Medical Oncology Department
    University Hospital A Coruña
    Head of Clinical Research Program in Oncology
    Biomedical Research Institute (INIBIC) 
    A Coruña, Spain

    Disclosures

    Disclosure: Rosario García Campelo, MD, has the following relevant financial relationships: 
    Advisor or consultant for: AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Janssen; Lilly; Merck Sharp & Dohme; Roche; Sanofi; Takeda
    Speaker or a member of a speakers bureau for: AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Janssen; Lilly; Merck Sharp & Dohme; Roche; Takeda

  • Ignacio I. Wistuba, MD

    Head ad interim 
    Division of Pathology and Laboratory Medicine
    Chair, Department of Translational Molecular Pathology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas, United States

    Disclosures

    Disclosure: Ignacio I. Wistuba, MD, has the following relevant financial relationships: 
    Advisor or consultant for: AstraZeneca/Medimmune; Asuragen; Bayer; Bristol Myers Squibb; Flame; GlaxoSmithKline; Guardant Health; HTG Molecular; Merck Sharp & Dohme; Novartis; Oncocyte; Pfizer   
    Speaker or a member of a speakers bureau for: AstraZeneca; Daiichi Sankyo; Genentech/Roche; Merck Sharp & Dohme; Pfizer; Platform Health
    Grants for clinical research from: Adaptimmune; Adaptive; Akoya; Amgen; Bayer; Bristol Myers Squibb; DepArray; EMD Serono; Genentech; HTG Molecular; Iovance; Johnson & Johnson; Karus; Medimmune; Merck Sharp & Dohme; Novartis; Oncoplex; Pfizer; Takeda; 4D

Editors

  • Megan Cannon, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Megan Cannon, PhD, has disclosed no relevant financial relationships.

  • Eloise Ballard, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Disclosure: Eloise Ballard, PhD, has disclosed no relevant financial relationships.

CME Reviewer

  • Esther Nyarko, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships. 


Accreditation Statements

Developed through a partnership between Medscape and International Association for the Study of Lung Cancer (IASLC).



In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Best Practices in Diagnosing and Managing EGFR Exon 20 Insertion-Mutated NSCLC: Current and Future Outlook

Authors: D. Ross Camidge, MD, PhD; Rosario García Campelo, MD; Ignacio I. Wistuba, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC Released: 10/1/2021

Valid for credit through: 10/1/2022

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Best Practices in Diagnosing and Managing EGFR Exon 20 Insertion-Mutated NSCLC: Current and Future Outlook

Dr Camidge introduces the program on diagnosing and managing EGFR exon 20 insertion-mutated NSCLC.
D. Ross Camidge, MD, PhD

EGFR Exon 20 Insertion-Mutated NSCLC: Response to Current Therapies

Dr Camidge and Dr García Campelo discuss the epidemiology of EGFR exon 20 insertion mutations, their clinical significance, and remaining challenges.
D. Ross Camidge, MD, PhD; Rosario García Campelo, MD

Diagnosing EGFR Exon 20 Insertions in the Clinic: Key Challenges

Dr Camidge and Dr Wistuba provide perspectives on molecular testing and how clinics can improve their diagnostic capabilities and outcomes.
D. Ross Camidge, MD, PhD; Ignacio I. Wistuba, MD

New and Emerging Therapies for EGFR Exon 20 Insertion-Mutated NSCLC: Expert Insights

Dr Camidge and Dr García Campelo discuss the implications of the clinical evidence for novel and emerging therapies targeting EGFR exon 20 insertion-mutated NSCLC.
D. Ross Camidge, MD, PhD; Rosario García Campelo, MD

Best Practices in Diagnosing and Managing EGFR Exon 20 Insertion-Mutated NSCLC: Conclusions and Takeaway Messages

Join Dr Camidge as he summarizes key take-home messages from the program.
D. Ross Camidge, MD, PhD
 

Educational Impact Challenge

The goal of this activity is to increase clinicians' awareness of exon 20 insertions within EGFR-mutated non-small cell lung cancer (NSCLC), their detection and diagnosis, and the potential role of emerging targeted therapies in the treatment paradigm for EGFR exon 20 insertion mutations in NSCLC.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print